ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Q2 2025 Earnings Call Transcript

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Q2 2025 Earnings Call Transcript August 13, 2025

ARS Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $-0.46 EPS, expectations were $-0.41.

Operator: Good morning and welcome to the ARS Pharmaceuticals Conference Call. [Operator Instructions] Please be advised today’s conference is being recorded. I’ll now turn the call over to Justin Chakma, the Chief Business Officer. Please go ahead.

Justin Chakma: Good morning, and thank you...